Objective: There is little detailed phenotypic characterization of bilateral hippocampal sclerosis (HS). We therefore conducted a multicenter review of people with pharmacoresistant epilepsy and bilateral HS to better determine their clinical characteristics. Methods: Databases from 11 EPIGEN centers were searched. For identified cases, clinicians reviewed the medical notes, imaging, and electroencephalographic (EEG), video-EEG, and neuropsychometric data. Data were irretrievably anonymized, and a single database was populated to capture all phenotypic information. These data were compared with phenotyped cases of unilateral HS from the same centers.
Results: In total, 96 patients with pharmacoresistant epilepsy and bilateral HS were identified (43 female, 53 male; age range = 8-80 years). Twenty-five percent had experienced febrile convulsions, and 27% of patients had experienced status epilepticus. The mean number of previously tried antiepileptic drugs was 5.32, and the average number of currently prescribed medications was 2.99; 44.8% of patients had cognitive difficulties, and 47.9% had psychiatric comorbidity; 35.4% (34/96) of patients continued with long-term medical therapy alone, another 4 being seizure-free on medication. Sixteen patients proceeded to, or were awaiting, neurostimulation, and 11 underwent surgical resection. One patient was rendered seizure-free postresection, with an improvement in seizures for 3 other cases. By comparison, of 201 patients with unilateral HS, a significantly higher number (44.3%) had febrile convulsions and only 11.4% had experienced status epilepticus. Importantly, 41.8% (84/201) of patients with unilateral HS had focal aware seizures, whereas such seizures were less frequently observed in people with bilateral HS, and were never observed exclusively (P = .002; Fisher's exact test). Significance: The current work describes the phenotypic spectrum of people with pharmacoresistant epilepsy and bilateral HS, highlights salient clinical differences from patients with unilateral HS, and provides a large platform from which to develop further studies, both epidemiological and genomic, to better understand etiopathogenesis and optimal treatment regimes in this condition.
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| INTRODUCTION
The most common identifiable cause of pharmacoresistant focal epilepsy in adults is hippocampal sclerosis (HS). In unilateral HS, surgical resection of the affected hippocampus can associate with seizure freedom in up to 70% of cases. 1, 2 However, it has long been appreciated that there are cases of drug-resistant focal epilepsy in which HS is bilateral. For example, in 1958 Wilder Penfield identified 2 cases that developed profound memory difficulties following standard left temporal lobectomy. He hypothesized that these 2 patients had significant, but unsuspected, right hippocampal pathology such that when he resected the left hippocampus the effect was similar to bilateral temporal lobectomy. 3 Penfield's theory was substantiated many years later when one of his cases was analyzed at autopsy and was found to have right-sided hippocampal atrophy. 4 Penfield's noble publication, in which he illustrated unforeseen complications of resective surgery, led Scoville to contact him and highlight the case of Henri Molaison (Patient HM), who had undergone bilateral temporal lobectomies and subsequently developed dense anterograde amnesia. Milner traveled to Connecticut to study HM and it quickly became evident that bilateral temporal lobectomy was contraindicated owing to the profound cognitive sequelae. 5, 6 Such observations, now 6 decades old, emphasize that bilateral hippocampal pathology can pose many
Key Points
• Bilateral HS is a relatively rare, but important, cause of pharmacoresistant epilepsy
• 25% of people with bilateral HS experienced a febrile seizure, and no patient had focal aware seizures alone
• 27% of patients with bilateral HS had experienced status epilepticus, not necessarily at the onset of seizures
• Patients with bilateral HS had often tried many antiepileptic medications and had high rates of cognitive and psychiatric comorbidity
• In this multicenter study, only a minority of patients with bilateral HS proceeded to surgical (palliative) resection of 1 hippocampus difficulties. The development of magnetic resonance imaging (MRI) has enabled much better detection of bilateral HS, 7 a condition in which seizures are perceived to be very drug resistant and surgical options seem limited. The exact incidence of bilateral HS is unknown, and there is little work specifically examining the phenotypic characteristics of patients with bilateral HS, particularly in patients with bilateral HS who do not proceed to surgical treatment. To address this, we evaluated the characteristics and management of patients with bilateral HS across a multicenter consortium.
| MATERIALS AND METHODS
EPIGEN is an international consortium of tertiary referral epilepsy centers that aims to deliver clinically facing genomic research. All full member institutions of EPIGEN (see Table S1 for details) searched clinically held databases for patients with bilateral HS. Inclusion criteria were kept deliberately broad (Table S2) , with the principal criterion being that patients had to have evidence of bilateral HS on an epilepsy protocol brain MRI, as determined by a neuroradiologist and/or epileptologist. Bilateral HS was defined as demonstration of significant atrophy of both hippocampi with or without increase in signal of 1 or both hippocampi. Male and female patients of any age were included, as were patients with dual pathology detected on brain imaging. We also specified that patients had to have tried ≥2 appropriate antiepileptic drugs (AEDs) to enable study of patients with bilateral HS and pharmacoresistant epilepsy. Detailed phenotypic analysis was performed through thorough review of medical notes/clinical databases including imaging reports, electroencephalographic (EEG)/video-EEG recordings, neuropsychometric assessments, operation notes, histology reports, and clinical outcomes. Data were entered based on the medical information held at the EPI-GEN center and collected to the point at which medical documentation at the EPIGEN center ceased.
Phenotypic data were deidentified and entered into a database with 25 principal entry fields (Table S3) . Researchers were encouraged to leave fields blank if there was any uncertainty. All data were pooled, and two of the authors (A.S. and P.D.) analyzed the data. Any disagreements in data interpretation were resolved through careful discussion. Qualitative evaluation and relevant quantitative analyses were performed. We also collected data from a large collection of patients with unilateral HS attending the same EPIGEN centers to allow comparison of phenotypic characteristics between people with bilateral and unilateral HS.
| RESULTS

| Basic phenotypic data
Nine centers identified patients from databases (range = 116-5000 patients), and 2 centers identified patients from clinics (average = 1500-2000 patients per year). Ninety-six patients with bilateral HS who met the inclusion criteria were studied (43 female, 53 male). The ethnic diversity of included patients reflects the centers that contribute to EPIGEN. The majority were Caucasian (72/96), 9 were of Asian descent (3 Indian, 4 Chinese, 2 not further specified), and 4 of African heritage. Racial origin was not documented formally in 11 cases.
The duration of follow-up at the EPIGEN centers ranged from 4 weeks to 58 years (mean = 7.5 years). The age at time of data capture ranged from 8 to 80 years (mean = 49. 
| Etiopathogenesis of epilepsy
Of the 96 patients studied, 14 (14.5%) had a confirmed family history of epilepsy. However, in only 4 (4.2%) patients was epilepsy identified in first-degree relatives and in 2 of these the family member's epilepsy was acquired (posttraumatic epilepsy, brain tumor).
The majority of patients did not have a documented history of febrile seizures (63 no evidence of febrile seizures; 9 not documented). In the 24 (25.0%) patients who did have febrile seizures, 2 had prolonged febrile seizures. Interestingly, 5 patients who had febrile seizures had a positive family history of epilepsy, although in 1 case the affected relative had an acquired cause for their epilepsy. Similarly, 4 patients who had febrile seizures had additional clearly defined etiologies for developing epilepsy (1 had meningitis in childhood, 2 had meningoencephalitis in adulthood, and 1 had neurosurgery in childhood [burr holes] owing to presumed intracranial hemorrhage).
The most common identifiable cause for bilateral HS was infection, principally meningoencephalitis ( Figure 1 ). Four patients developed epilepsy secondary to birth trauma and 4 after traumatic brain injury outside of the neonatal period. Similarly, 4 patients developed bilateral HS following new onset refractory status epilepticus (NORSE). Three patients were found to have a potentially causal autoantibody (1 voltage-gated potassium channel antibody, 1 antiglutamic acid decarboxylase antibody, and 1 not further specified) and were therefore classified as autoimmune epilepsy. The proportion of cases tested for autoantibodies was low (12/94 cases; 2 patients had no data available), likely reflecting that cases were acquired over decades and many patients had a diagnosis of bilateral HS long before antibody-mediated epilepsy was recognized or specific antibody testing was available. In the majority of cases, 61 of 96 (63.5%), no cause was identified.
| Seizure type
In averaging all cases where a seizure frequency per month was recorded or could be derived (eg, investigatorrecorded seizure frequency per week), the mean seizure frequency was 10.9 seizures per month. Seizure type was analyzed in detail ( Figure 2 ). The majority of patients had either focal seizures with impaired awareness or focal to bilateral tonic-clonic seizures (44/96; 45.8%). Focal impaired awareness seizures alone occurred in 23 of 96 (23.9%), and focal seizures with or without impairment of awareness and focal to bilateral tonic-clonic seizures in 16 of 96 (16.7%). Four patients were reported to have bilateral tonic-clonic seizures alone. No patient had only focal aware seizures. Most patients (64/96; 66.7%) did not experience status epilepticus either at outset or at any point thereafter. In total, 26 (27.1%) patients had a previous history of status epilepticus and in 6 cases this information was not recorded.
| Medication history
Patients included in this cohort had pharmacoresistant epilepsy, and many patients had tried multiple AEDs. Only 7 cases did not have full datasets available for previously trialed medication, and data were virtually complete for currently prescribed treatments. The mean number of AEDs previously tried was 5.32 (range = 1-15). The average number of currently prescribed AEDs was 2.99 (range = 1-6).
The most commonly tried AED was carbamazepine, followed by, in descending order, valproate, lamotrigine, phenytoin, and levetiracetam ( Figure 3A ). In contrast, levetiracetam was the most commonly prescribed current AED, followed by, again in descending order, lamotrigine, clobazam, valproate, and carbamazepine ( Figure 3B ). Various other second and third line AEDs also either had been tried previously or were being prescribed as a current medication. In a small number of cases, intravenous immunoglobulin was given owing to a putative autoimmune etiology. Steroids may also have been prescribed for these patients and possibly plasma exchange. However, no definitive comments can be made on immunomodulation administered to patients with bilateral HS, as most centers did not document medications beyond conventional AEDs.
| Comorbidities
Many patients with bilateral HS had not undergone formal neuropsychometric testing, with neuropsychometric scores only rarely given. Almost half of the patients were reported to have some cognitive impairment. In 17 of 96 (17.7%), memory impairment was identified, and an additional 26 of 96 or 27.1% were reported to have cognitive difficulties (21 had intellectual difficulties, and 5 had nonspecified cognitive impairment). One patient was reported to have learning difficulties, 3 of 96 (3.1%) had developmental delay, and 1 patient had attention-deficit/hyperactivity disorder ( Figure S1A ). In 42 of 96 cases (43.8%) there was no evidence for cognitive impairment, and in 6 (6.3%) cases insufficient information was recorded.
Psychiatric comorbidity ( Figure S1B ) affected almost half of the patients (46/96; 47.9%), with particular representation of depression, anxiety, or both. A small number (4/96; 4.2%) developed interictal psychosis, with 4 patients having experienced postictal psychosis. Three patients had dissociative seizures, and 2.1% (2/96) had misused recreational substances.
These patients also experienced many other medical comorbidities, particularly osteoporosis (6/96; 6.3%) and headache (5/96; 5.2%; data not shown).
| Investigations
Only patients with radiologically confirmed bilateral HS were included. MRI also revealed additional cavernomas in 3 (3.5%) patients, posttraumatic change in 2 (2.4%), and cortical dysplasia in 1. Figure S2A,B) . Thirty-six (37.5%) had bitemporal interictal discharges, with 14 of these 36 (38.9%) reporting no cognitive impairments, whereas 22 of 36 (61.1%) had cognitive impairment/intellectual disability/ learning disability, or memory impairment. One-quarter of cases (24/96; 25.0%) had bilateral onset of seizures, and a majority of this group (18/24; 75.0%) had cognitive difficulties.
Eleven (11.5%) patients underwent intracranial EEG recordings, and of these, seizures had unilateral temporal onset in 5 (1 right, 4 left), bitemporal onset in 4, unilateral hemispheric onset in 1, and multifocal onset in 1 (Table S4) . Only 17 (17.7%) patients underwent Wada (sodium amobarbital) testing; perhaps as many had already been determined not to be a candidate for surgical resection. Although difficult to interpret in isolation, Wada testing did demonstrate left hemispheric dominance in most cases.
| Surgical interventions
A total of 18 (18.75%) patients underwent epilepsy surgery (intracranial recording and/or resection). Of the 11 patients who underwent intracranial EEG monitoring, 4 subsequently had a resection (anterior temporal lobectomy, selective amygdalohippocampectomy, or corticectomy). Seven patients had single stage resections (Table S4 ). In 8 of the temporal lobectomies, HS was confirmed on pathological analysis, with no histopathological data available for the other 2 cases. In the patient who underwent corticectomy, nonspecific findings were demonstrated.
| Outcomes
Outcome to the point of the most recent appointment at the EPIGEN center was recorded (Figure 4 ). In 23 (24.0%) cases outcome data were not recorded, and 1 patient died. Four patients were seizure-free on antiepileptic medication alone (4/96; 4.2%). Of the 11 patients who underwent surgical resection, only 1 patient was rendered completely seizure-free, and 3 (27.3% of patients who had undergone resection) showed improvement in seizure frequency.
Around one-third of patients continued with medical management alone (34/96; 35.4%). A proportion of patients underwent, or are considering, neurostimulation therapy with either vagal nerve stimulation (9/96; 9.4%), responsive neurostimulation (6/96; 6.3%), or in 1 case both.
| Comparison of people with bilateral HS to those with unilateral HS
We specifically wished to delineate how specific certain findings were to bilateral HS. We therefore compared our 96 patients with 201 cases of unilateral HS from EPIGEN centers. Of these 201 cases, 199 had pharmacoresistant epilepsy, with 2 having ongoing seizures despite an adequate trial of 1 AED, and 154 had proceeded to surgical resection. Key comparative phenotypic data from the patients with unilateral HS are highlighted in Table 1 . As illustrated, patients with unilateral HS were significantly more likely to have experienced febrile seizures (44.3% compared to 25% in bilateral HS; P = .0002; Fisher's exact test) and were less likely to have experienced status epilepticus (11.4% in unilateral HS vs 27.1% in bilateral HS). 
F I G U R E 4
Overall outcomes in patients with bilateral hippocampal sclerosis (HS). The majority of patients with bilateral HS persisted with medical treatment alone. Eleven patients had resective surgery with either anterior temporal lobectomy (ATL), selective amygdalohippocampectomy (SAH), or corticectomy; 4 underwent prior intracranial electroencephalographic monitoring (ICEEG), and 7 patients had single stage resections. Seven underwent ICEEG without subsequent resection. Sixteen patients had undergone, or were awaiting, neurostimulation. Four (4.2%) became seizure-free on medication alone. RNS, responsive neurostimulation. VNS, vagus nerve stimulation Some caution must be applied to statistical analysis of status epilepticus, as data were not provided for more than half of patients with unilateral HS. Also, whereas focal aware seizures were a common seizure type in patients with unilateral HS, being found in 84 cases (41.8%), such seizures were less frequent in people with bilateral HS (P = .002; Fisher exact test), and no patient with bilateral disease had only focal aware seizures.
| DISCUSSION
The current study is the largest phenotypic characterization of bilateral HS and epilepsy to date. Importantly, the study collates data from multiple epilepsy centers, thereby reducing bias and better reflecting "real-life" clinical practice across multiple countries. Previous work [8] [9] [10] [11] is summarized in Table 2 , coupled with a summary of our data. The contralateral hippocampus in patients with unilateral HS may have certain imaging changes [12] [13] [14] [15] or pathological features detected at postmortem. 16 Volumetry, particularly with appropriate normalization to control values, enhances detection of bilateral hippocampal atrophy, 13, 15, 17 and in studies of patients with unilateral HS, the contralateral hippocampus can be significantly smaller than control hippocampi although also larger than the hippocampus ipsilateral to the lobectomy. 15 Magnetic resonance (MR)
techniques have been utilized in attempts to refine bilateral mesial temporal lobe epilepsy (mTLE) and, for example, predict surgical outcome in patients with bilateral hippocampal atrophy. 18 There are also some patients with bilateral HS who are drug responsive. Inclusion of drug responsive cases or those with hippocampal atrophy defined by volumetric MR analysis would have increased the number of people studied, but our aim was to better describe patients with pharmacoresistant epilepsy and bilateral HS visible on MRI in a standard clinical setting to determine whether detailed phenotypic analysis might offer insights to improve clinical care going forward.
Of the 96 patients we studied, most (1) had a very high number of seizures per month, (2) had previous exposure to multiple AEDs, and (3) were on average taking around 3 AEDs concurrently. The pattern of drug prescription likely mirrors trends in clinical practice. Some patients had very long epilepsy histories, and it is perhaps unsurprising that a majority of patients had been exposed to carbamazepine, although this was not a common current prescription, with levetiracetam and lamotrigine now being favored.
Complex febrile seizures (either prolonged convulsion, convulsion associated with unilateral weakness, or febrile status epilepticus in childhood) associate with an increased risk of subsequently developing epilepsy. 19, 20 Some studies have reported an incidence of febrile seizures of nearly 50% in patients with unilateral HS, 21 and our data detected febrile seizures in 44.3% of unilateral HS cases. Similarly, previous work has shown that in patients with temporal lobe epilepsy and a background of febrile convulsions, a majority will have unilateral hippocampal atrophy. 17 As in other work, 10 a relatively smaller proportion of our patients with bilateral HS had a history of febrile seizures (26%), and only 2 cases in this cohort had prolonged febrile convulsions. Five patients with febrile seizures also had a family history of epilepsy, although full information about family history of epilepsy may be lacking, as the study did not include acquisition of detailed family pedigrees. Previous genome-wide association studies have suggested a possible association of mTLE in patients who have previously had febrile convulsions and mutations in the SCN1A gene. 22 However, in the current cohort those who had a history of febrile seizures often also described other risk factors for developing bilateral HS, for example, a subsequent meningoencephalitic illness. Although chronic epilepsy, even in patients with preexisting hippocampal malformations, does not necessarily result in HS, 23 it is well recognized that prolonged status epilepticus can result in profound hippocampal volume loss and associate with subsequent pharmacoresistant epilepsy. 24 Although patients from the latter category are represented in the current cohort, for example the 4 patients in whom NORSE was recorded as the underlying etiology, most patients did not have a history of status epilepticus. The most common etiology was infection, and other work has also demonstrated that bilateral hippocampal atrophy may be more likely after a meningitic or encephalitic illness.
17
A small number of patients were demonstrated to have a potentially causal antibody, but this proportion may be higher in future studies, as more antibodies implicated in the pathogenesis of epilepsy are identified and testing for such antibodies increases.
Despite the large number of cases included here, it is not possible to define an exact etiology for bilateral HS. There are features to suggest that bilateral HS is a different entity than unilateral HS, but it may be that bilateral hippocampal damage represents the final common pathway of a heterogeneous collection of rare epilepsy syndromes. Similar to the increasing recognition that antibody-mediated disease may contribute to refractory | 1417 status epilepticus, it can be speculated that certain insults, perhaps particularly infection, may lead to development of bilateral HS in people with a genetic susceptibility to this condition. Intriguingly, no patient with bilateral HS had only focal aware seizures, and the incidence of focal aware seizures overall (ie, even when considered in combination with other seizure types) was also significantly lower than in patients with unilateral HS. The exact reasons for this are uncertain. It might, for example, be that an individual seizure from a diseased hippocampus will likely cause impairment of awareness in the presence of an anatomically abnormal contralateral hippocampus.
As would be predicted in a group of patients with pharmacoresistant epilepsy, there were high rates of cognitive and psychological comorbidity. Were all patients to have neuropsychometric testing, the incidence of cognitive impairment might be higher, particularly as people with unilateral HS may be below the 50th percentile in all cognitive domains. 25 There was also a high degree of psychopathology, with more than one-third of patients reporting depression, anxiety, or both. Again, one may predict higher rates of psychiatric symptomatology were this to be formally evaluated for all patients. Only 11 (11.5%) patients proceeded to resective surgery, which is low compared to other studies. In 1996, Arruda and colleagues evaluated 74 consecutive patients with mTLE undergoing surgical resection. When measured by volumetry, 17 of these cases had bilateral hippocampal atrophy, and although the outcomes in this group were less favorable than in unilateral HS, 61.7% had class I or II outcome according to Engel's modified classification. 26 More recently, Vanli-Yuvaz and colleagues reviewed 124 patients who had undergone epilepsy surgery for HS at their center in Turkey. 11 In that study, 93 patients had unilateral HS and 31 had bilateral HS. The authors report that 16.1% of bilateral HS patients were not pharmacoresistant and that 6 of 9 patients with bilateral HS who underwent unilateral temporal lobectomy were rendered seizure-free. 11 Similarly, in 2013 Malter and colleagues evaluated patients at a single center in Germany. 9 They identified 31 cases of bilateral HS, and 11 of these proceeded to surgery with resection of the putatively more epileptogenic hippocampus. Of those that did progress to surgery, seizure freedom rates at 12 and 24 months were similar to cases of unilateral HS, and no patient with bilateral HS became globally amnestic postresection. An older study evaluated 28 patients with bilateral independent temporal lobe seizures detected with intracranial recording, of whom 15 proceeded to resection. 27 Ten patients were rendered seizure-free, and of those, 7 were shown to have unilateral HS on imaging or a lateralized Wada result. In the 5 who had persistent seizures, such structural or functional lateralization was not evident. 27 In our study, only a single patient became sei- 29, 30 Given that video-telemetry is typically of 1-2 weeks' duration, this may artificially skew interpretation if all, or most, of the seizures during EEG recording happen to arise from one of the sclerosed hippocampi. At a pathological level, those patients who underwent temporal lobectomy were found to have HS on histopathological examination, where this was available. Interesting work has shown that in postmortem cases of HS there can be bilateral accumulation of tau deposits within the sclerosed hippocampus 31 and bilateral dentate granule cell dispersion. 16 The contributions that such bilateral pathology may make to cognitive difficulties and/or epileptogenesis, particularly in patients in whom bilateral HS is detected in vivo, would be worthy of further investigation. The current work would suggest that proceeding to resection in patients with bilateral HS is not common in real life practice and is perhaps viewed more as a palliative, rather than a curative, procedure, even at specialist centers that are able to offer the range of epilepsy surgeries available. Moreover, the presence or absence of focal aware seizures might be valuable in stratifying potential epilepsy surgical candidates going forward. For example, the presence of focal aware seizures might be indicative of unilateral HS, and perhaps more importantly, the absence of focal aware seizures in a patient without obvious markers of bilateral HS might be indicative of bilateral disease and consequently a poorer postoperative prognosis. Careful delineation of seizure phenotype could therefore offer insights into the possibility of subclinical bilateral disease, just as Penfield was attuned to so many years ago.
| Limitations
This study was limited to retrospective review of patient data held at the individual EPIGEN centers. Despite making data entry fields formulaic, there were inevitable subjective differences in the way individual investigators entered data. Although objective information was provided for the majority of patients for certain fields (eg, seizure type and medications), more subjective data fields such as cognitive and psychological difficulties were less complete, restricting interpretation. Similarly, there are limitations in retrospectively comparing bilateral HS cases to patients with unilateral HS even if the cases are drawn from the same epilepsy centers-more patients with unilateral HS having had formal neuropsychometric and neuropsychiatric evaluations, for example. A well-defined multicenter prospective study examining patients with bilateral HS and comparing such patients to prospectively phenotyped cases of unilateral HS would seem worthwhile.
| CONCLUSIONS
Patients with pharmacoresistant epilepsy and bilateral HS can pose significant challenges to clinicians tring to ameliorate both seizures and associated comorbidities. In the current study, which samples clinical practice across multiple centers in different countries, such patients are shown to (1) have frequent seizures with no patient having focal aware seizures alone, (2) have a relatively low frequency of febrile seizures compared to unilateral HS, (3) often have no identified etiology for the bilateral HS, and (4) do not often proceed to surgical resection. A prospective study examining a large series of cases with bilateral HS, building on data presented here, would help to better inform etiology as, for example, antibody testing becomes more established. Similarly, genomic work in a well-phenotyped group of patients with bilateral HS might provide further distinctions from unilateral HS. Epidemiological work is also required to better determine whether a more aggressive or more circumspect approach is appropriate when deciding to offer unilateral hippocampectomy to patients with bilateral disease.
